Format

Send to

Choose Destination
Retina. 2015 Mar;35(3):381-91. doi: 10.1097/IAE.0000000000000466.

Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration.

Author information

1
*Department of Ophthalmology, Albany Medical Center, Lions Eye Institute, Albany, New York; †Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; ‡Department of Ophthalmology, University of California, Shiley Eye Center, Institute for Genomic Medicine, La Jolla, California; and §Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota.

Abstract

PURPOSE:

To determine whether there is an association between response to intravitreal anti-vascular endothelial growth factor agents and genotype in patients with neovascular age-related macular degeneration.

METHODS:

Analysis of the current literature evaluating pharmacogenetics of treatment response in patients with neovascular age-related macular degeneration.

RESULTS:

Studies have demonstrated associations between various genotypes and response to intravitreal anti-vascular endothelial growth factor agents. Lower-risk genotypes of the CFH, ARMS2, HTRA1, and VEGF-A genes may be associated with improved visual outcomes. Additionally, frequency of injections may be associated with certain genotypes.

CONCLUSION:

Genetic background may influence an individual's response to treatment of neovascular age-related macular degeneration. Further studies to investigate biologic pathways of neovascular age-related macular degeneration and gene products that are directly involved might lead to better understanding of contribution of various genes to treatment response.

PMID:
25635578
DOI:
10.1097/IAE.0000000000000466
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center